重组人血管内皮抑制素联合培美曲塞顺铂治疗晚期非小细胞肺癌临床疗效分析.docVIP

重组人血管内皮抑制素联合培美曲塞顺铂治疗晚期非小细胞肺癌临床疗效分析 　　【摘要】 目的：探讨重组人血管内皮抑制素和培美曲塞+顺铂联合治疗晚期非小细胞肺癌（NSCLC）的临床疗效。方法：选取2010年1月-2012年 　　1月笔者所在医院收治的晚期NSCLC患者76例，随机分为观察组和对照组，每组38例，对照组仅给予培美曲塞+顺铂化疗，观察组在上述治疗基础上给予重组人血管内皮抑制素（恩度）治疗，观察并比较两组患者临床疗效及不良反应发生情况。结果：观察组临床总有效率、临床获益率均明显高于对照组（P0.05）。观察组患者1年生存率和中位疾病进展时间均明显高于对照组，差异均有统计学意义（P0.05）。结论：重组人血管内皮抑制素联合培美曲塞+顺铂治疗晚期非小细胞肺癌的临床疗效显著，不良反应小，患者临床收益率高，可在临床推广应用。 　　【关键词】 非小细胞肺癌； 重组人血管内皮抑制素； 培美曲塞； 顺铂 　　中图分类号 R734.2 文献标识码 A 文章编号 1674-6805（2015）16-0005-02 　　【Abstract】 Objective：To investigate the clinical efficacy of Recombinant Human Endostatin combined with Pemetrexed and Cisplatin in the treatment of advanced non-small cell lung cancer（NSCLC）.Method：76 patients with advanced NSCLC in our hospital were randomly divided into the observation group and the control group，38 cases in each group.The cases in the control group only received Pemetrexed and Cisplatin，while the cases in the observation group received administration of Recombinant Human Endostatin treatment on the basis of the above.The clinical efficacy and adverse events of two groups were observed and compared.Result：The total clinical efficiency and clinical benefit rate of the observation group were significantly higher than those of the control group（P0.05）. 　　1-year survival and median time to progression of the observation group were significantly higher than those of the control group，the differences were statistically significant（P0.05）.Conclusion：The clinical efficacy of Recombinant Human Endostatin combined with Pemetrexed and Cisplatin in the treatment of advanced non-small cell lung cancer are significant，less side effects，which can be applied in clinic. 　　【Key words】 Non-small cell lung cancer； Recombinant Human Endostatin； Pemetrexed； Cisplatin 　　First-author’s address：Hu’nan Cancer Hospital，Changsha 410013，China 　　doi：10.14033/j.cnki.cfmr.2015.16.003 　　肺癌是发病率和死亡率增长最快，对人群健康和生命威胁最大的恶性肿瘤之一，近50年来，世界范围内发病率、死亡率均较明显增高，严重威胁人们的生命健康。其中，肺癌各种病理类型中，尤以非小细胞肺癌（NSCLC）发病率最高，占肺癌发病率的75%～80%，居于恶性肿瘤死亡率之首[